Custom Peptide Synthesis: From Sequence Brief to Pilot Batch

Custom Synthesis | 2026-09-13 | 14 min read

A practical custom peptide synthesis workflow covering sequence briefs, modifications, SPPS, purification, analytical release, pilot batches, and scale-up decisions.

A custom peptide project begins with an unambiguous brief

Custom peptide synthesis is not simply a request for a sequence and a price. The same sequence string can describe different materials when terminal groups, stereochemistry, cyclization, counterions, isotope labels, purity basis, or formulation requirements are left unstated. A clear brief reduces rework and gives the buyer a defensible basis for comparing pilot-batch results.

This guide is written for lawful laboratory research, assay development, and B2B sourcing. It is not a clinical manufacturing protocol and does not provide personal-use instructions.

Step 1: Freeze the identity specification

The first page of a project brief should define the molecular identity in a way that a chemist, analytical scientist, and procurement specialist can read the same way. Include the one-letter or three-letter sequence, direction, terminal groups, noncanonical residues, disulfide or cyclization pattern, D-amino-acid positions, and expected molecular mass.

Also state what is not requested. For example, an all-L linear peptide is not the same as a D-retro-inverso analog, and a peptide acetate is not automatically equivalent to a peptide TFA salt. If the project uses a blend, define each component and the target ratio separately.

Step 2: Define scale and material basis

The word scale can refer to synthesis input, crude peptide amount, purified peptide amount, or number of vials. A useful request separates these units. Ask for the target output as net peptide content, not only gross lyophilized cake weight, and state whether the pilot batch is for analytical feasibility, assay screening, or a larger manufacturing decision.

Important fields include:

• Target net amount and acceptable overage.
• Desired purity threshold and how purity will be reported.
• Vial size, fill configuration, and packaging.
• Required sample quantity for analytical testing.
• Timeline assumptions for design review, synthesis, purification, and release.

This structure makes quotes more comparable. A lower price may reflect a lower net amount, a different purity basis, fewer analytical samples, or a different packaging scope.

Step 3: Understand the SPPS and purification decision points

Solid-phase peptide synthesis (SPPS) builds the chain stepwise on a resin. Longer sequences, hydrophobic regions, aggregation-prone segments, unusual residues, and difficult couplings can reduce crude quality and affect purification yield. The buyer does not need to dictate every chemistry choice, but the project should identify known sequence risks and the point at which the synthesis team will propose a change.

Purification is not a single word either. Reverse-phase HPLC, ion-exchange methods, size-based methods, and other approaches can have different selectivity and recovery. The final method should be selected with the identity, impurity profile, target purity, scale, and intended assay in mind.

Ask the project team to distinguish crude yield, purified yield, recovery, and final net content. These metrics answer different questions and should not be collapsed into one percentage.

Step 4: Agree on analytical release before synthesis

Analytical testing should be agreed before the pilot batch is made. At minimum, the project should identify how identity and chromatographic purity will be assessed. Depending on the sequence and research purpose, the package may also require mass confirmation, sequence-specific evidence, water, residual solvents, counterion, endotoxin, bioburden, or elemental analysis.

An HPLC area result can support a purity statement, while mass spectrometry can support expected molecular mass. Neither automatically resolves every possible isomer or stereochemical question. The risk of the identity should determine whether an orthogonal method is needed.

Define acceptance criteria in a table with four columns: attribute, method, acceptance criterion, and reporting format. This avoids a common failure mode in which a supplier says a batch is released, but the buyer later learns that the test scope was never defined.

Step 5: Use the pilot batch as a learning gate

A pilot batch should answer more than whether material can be made. It should test whether the identity specification is practical, whether the purification method provides enough selectivity, whether the analytical method is fit for purpose, and whether the packaging format protects the material during handling.

At the pilot review, compare planned and actual results:

• Sequence and modification match.
• Crude profile and major impurity classes.
• Purified recovery and net content.
• HPLC and identity results.
• Water, residual solvent, or counterion observations where relevant.
• Vial fill, closure, storage, and shipping condition.

The output should be a short deviation and learning report. A pilot that fails to meet a criterion can still be valuable if the failure is understood and the next design is explicit.

Step 6: Decide whether to scale

Scale-up should be a new decision, not an automatic repeat. Confirm that the sequence, raw-material controls, purification method, analytical release, and packaging can be transferred to the planned quantity. Ask how batch-to-batch comparability will be evaluated and which parameters are critical to the research program.

For recurring orders, keep a controlled master specification. Track supplier code, version, sequence, modifications, release methods, acceptance criteria, packaging, and approved changes. A product name alone is not enough to preserve comparability.

Custom synthesis questions for a supplier

• Can the supplier review the sequence and identify synthesis risks before quoting?
• Are terminal modifications, stereochemistry, and counterion defined?
• Is the price based on crude, purified, or net peptide amount?
• Which analytical methods and acceptance criteria are included?
• What changes require buyer approval?
• How are pilot-batch deviations documented?
• Can the released specification be reused for repeat B2B orders?

ZePeptide can coordinate research-use custom peptide specifications, pilot-batch questions, analytical documentation, and repeat-order planning. The final project should be approved by the laboratory's qualified technical staff.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.